Short answer
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed its Q3 2026 10-Q quarterly report on Sep 14, 2026 for the quarter ended Jul 31, 2026. Quarterly revenue was $31M (up 59.9% year over year) with net income of −$44M.
Q3 2026 key financials · XBRL
- Revenue
- $31M
- +59.9% YoY
- Net income
- −$44M
- −70.7% YoY
- Operating margin
- -121.6%
- Gross margin
- 56.5%
- EPS (diluted)
- −$0.75
- −50.0% YoY
Source: XBRL data from the KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) Q3 2026 10-Q on SEC EDGAR. USD.
KESTRA MEDICAL TECHNOLOGIES, LTD. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New 2026 Term Loan refinancing risk triggered by July 10 financing, including senior secured debt maturing July 10, 2031
- Liquidity risk with $244.7 million cash and investments against $32.3 million quarterly negative operating cash flow
- Reimbursement risk from Medicare, Medicaid, and private-payor coverage and collection requirements
- Operational risk from outsourced manufacturing of ASSURE® WCD components
- Competitive risk from continued investment needed to recruit, train, and retain the direct sales force
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other KESTRA MEDICAL TECHNOLOGIES, LTD. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.